mivacurium and Depressive-Disorder

Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to induce generalised seizures for the treatment of selected psychiatric disorders. The clinical indications for ECT as an effective therapeutic modality have been considerably expanded since its introduction. Anaesthesia and neuromuscular blocking agents (NMBAs) are required to ensure patients' safety during ECT. The optimal dose of muscle relaxant for ECT reduces muscle contractions without inducing complete paralysis. Slight residual motor convulsive activity is helpful in ascertaining that a seizure has occurred, while total paralysis prolongs the procedure unnecessarily. Suxamethonium is commonly used, but nondepolarising NMBAs are indicated in patients with certain comorbidities. In this review, we summarise current concepts of NMBA management for ECT.

Topics: Androstanols; Atracurium; Convulsants; Depressive Disorder; Electroconvulsive Therapy; gamma-Cyclodextrins; Humans; Isoquinolines; Mivacurium; Monitoring, Physiologic; Neuromuscular Blocking Agents; Neuromuscular Depolarizing Agents; Neuromuscular Nondepolarizing Agents; Rocuronium; Seizures; Succinylcholine; Sugammadex; Vecuronium Bromide

Topics: Adult; Aged; Anesthesia, General; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Isoquinolines; Male; Middle Aged; Mivacurium; Myasthenia Gravis; Neuromuscular Depolarizing Agents